The Trump administration doesn’t want to see hemp expanded nationwide in the next Farm Bill because of concerns about overproduction, an official said on February 21, 2018. The 2014 Farm Bill allowed hemp production in states with authorized hemp research projects. Greg Ibach, undersecretary for the U.S. Department of Agriculture, said, “One of the challenges we maybe have in the hemp industry is to make sure that demand and production coincide. We need to be careful so that we don’t kill the market for hemp by overburdening the market with supply before there is demand for it.”
Ibach also said that oversight of hemp should belong to the U.S. Department of Justice, which includes the Drug Enforcement Administration, not the USDA. The DEA appeared in court last week to argue that CBD, a molecule derived from hemp and marijuana, is an illegal drug and not authorized by the Farm Bill. A consortium of plaintiff’s including 12 year old Alexis Bortell, a former professional football player, a veteran and another child sued the government over legal access to CBD as a medicine.
In a well-documented personal drama, Alexis (who suffers from epilepsy), and her parents have sought to keep CBD as a legal option for her and others like her. Alexis tried over 20 other drugs before turning to CBD and her family was forced to relocate to Colorado from Texas to provide her the medicine. Alexis has not had a seizure in over three years. Nonetheless, the government says that cannabis has no medical applications whatsoever and is accordingly listed by the DEA as a Schedule 1 drug under the Controlled Substances Act. Alexis’ attorney believes that a ruling will eventually be made in her favor.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…